Prevention of Stroke: Carotid Artery Stenting or Endarterectomy?

Original Title: Long-Term Outcome after Carotid Artery Stenting. A Population-Based Matched Cohort Study.

Reference: Stroke. 2016 Jul 12. [Epub ahead of print].

 

Carotid Artery Stenting EndarterectomyIn the prevention of stroke, carotid artery stenting (CAS) is far less invasive than endarterectomy, but its long term outcomes remain unclear.

This large cohort study compared the long term outcomes of CAS vs. endarterectomy.

All patients included in the Swedvasc registry (National Swedish Vascular Registry) treated with CAS between 2005 and 2012 were identified. For every CAS procedure, 2 control endarterectomy procedures were included, matched by:

 

  • sex
  • age
  • year of procedure
  • indication (symptomatic/asymptomatic).

Primary end point was ipsilateral stroke, or death 30 days after procedure.

A total 1157 patients were included (409 CAS and 748 endarterectomy). Median age was 70 and 69% were symptomatic.

Risk factors were similar in both groups and the population was followed up at mean 4.1 years.

Death or stroke rates beyond the 30 days perioperative period occurred in:

  • 95 of 394 CAS patients (25.7%)
  • 120 of 724 endarterectomy patients (18.6%)

[Adjusted risk 1.59; CI 95% 1.15–2.18]

Death rate was:

  • 25.7% with CAS
  • 18.6% with endarterectomy

[HR 1.20; CI 95% 0.84–1.72]

Ipsilateral stroke rate was:

  • 9.4% with CAS
  • 2.9% with endarterectomy

[HR 3.40; CI 95% 1.53–7.53]

Any stroke + death after 30 days was:

  • 34.2% with CAS
  • 23.6% with endarterectomy

[HR 1.49; CI 95% 1.10–2.00]

 

Conclusion

In this cohort study, CAS was associated with a long term increased risk of ipsilateral stroke and death after perioperative period compared to endarterectomy.

 

Editorial Comment

Even though population was matched, some characteristics may be misleading in this kind of studies. Higher mortality in the CAS group cannot be explained by excessive ipsilateral stroke and may be due to higher global risk, which may have favored CAS indication, being less invasive.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...